A Pilot Study of Adoptive Immunotherapy Comprising 2-Methyl-3-Butenyl-1-Pyrophosphate-Stimulated Gamma Delta T Cells in Patients With advanced Renal Cell Carcinoma
Not Applicable
Recruiting
- Conditions
- advanced Renal cell carcinoma
- Registration Number
- JPRN-UMIN000016793
- Lead Sponsor
- Tokyo Women's Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
No C-reactive protein with an infectious disease that requires medication, No active infection with hepatitis virus or HIV, No poorly controlled DM or heart failure or arrhythmia, No autoimmune disease and interstitial pneumonia, No other malignancy, No bone of organ transplant recipient, Not pregnant nor nursing, No mental disorder in spite of standard therapy 3) Other patients judged to be ineligible by the attending investigators were also excluded from the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the factors of effective cases To analyze the factors of the patients who achieved CR, PR or SD by RECIST criteria
- Secondary Outcome Measures
Name Time Method